Vaccine and Infectious Disease Division
Nearly one-quarter of cancers worldwide are caused by infectious diseases. Pathogens, such as Human Herpesvirus 8 (HHV-8) and Epstein Barr Virus (EBV), have been identified as contributing factors in lymphoma, sarcoma, liver cancer, prostate cancer, bladder cancer and stomach cancer. Researchers hope to answer a number of key questions: How are cancer-causing infections transmitted and acquired? What factors govern the progression from chronic infection to cancer? Which therapies can be employed to prevent infection-related cancers? VIDD has recently fostered a pioneering collaboration with the Uganda Cancer Institute, the only cancer care facility in Uganda, to delineate and establish efficacious treatment options.
Research interests include targeting latent viral genomes for mutagenesis and disruption of viral pathogenesis and infection using engineered homing endonucleases.
Epidemiology, natural history, and treatment of human herpesvirus 8 infection and treatment of Epstein Barr Virus-associated lymphomas. HIV-related cance and infections as a complication of cancer care. Cancer epidemiology, pathobiology, treatment and training in resource-limited settings.
Phone: (206) 667-4600
Fax: (206) 667-1965
Immunologic endpoint determination for experimental vaccines (HIV, pneumococcus, malaria, TB, flu) and
Logistics, operations, quality assurance, and assay validation for immunologic evaluation of vaccines in the clinical trial setting
Clinical trials methodology; Vaccine evaluation; biomarker that predict an individual’s response to a given treatment and statistical analyses of vaccine trial data
Phone: (206) 667-6353
Fax: (206) 667-4378
HIV vaccine development and trial design, combination HIV prevention, mucosal immunology and mucosal sampling design in HIV prevention trials, the intersection of oncology and infectious disease, comparative effectiveness, decision analysis and health-related quality of life
Epidemiology, natural history, therapy, and prevention of HSV and other herpesvirus infections; interactions between HSV and HIV Vaccines and clinical trials
Phone: (206) 520-4340